How to win UKRI endorsement for the UK Global Talent visa.

Check Endorsed Funder Route eligibility first

The Endorsed Funder Route (EFR) is available to current holders of qualifying UKRI grants as PI, and to researchers who held such a grant within the past 5 years. Qualifying grants include: UKRI Future Leaders Fellowships, EPSRC Fellowships, BBSRC David Phillips Fellowships, MRC Career Development Awards, Wellcome Trust Investigator Awards (Wellcome is not a UKRI body but participates in the EFR), and a range of other named fellowships and programme grants — the full list is on the UKRI website and is updated periodically.

If you qualify for the EFR, the application is substantially simpler: you submit evidence of your qualifying award and a shorter personal statement. UKRI fast-tracks EFR applications with a target decision time of approximately 3–4 weeks rather than the standard 8 weeks. EFR applicants are automatically assessed under Exceptional Talent or Exceptional Promise depending on the nature of their award — most senior fellowship holders receive Talent, most early-career awards receive Promise.

The EFR is one of the most underused features of the Global Talent visa across all endorsing bodies. Many researchers with qualifying grants default to preparing a full standard-route application without checking the EFR list. Before doing anything else, visit the UKRI Global Talent Visa page and check the current list of qualifying awards against your grant history. If you held an EPSRC Fellowship, an MRC Career Development Award, or a UKRI Future Leaders Fellowship as PI within the past 5 years, the EFR route will save you weeks of preparation work and typically result in a faster decision.

Confirm UKRI scope if applying via the standard route

If you are not EFR-eligible, the standard route is open to any researcher whose work falls within UKRI's broad remit. UKRI is the right body for work that is interdisciplinary (spanning natural science, engineering, and humanities), applied or translational (bridging research and practice), or innovation-focused (commercialising research outputs through Innovate UK pathways).

If your work fits cleanly within one discipline and one other endorsing body's scope, consider whether that body might be more appropriate — a pure mathematician is better served by the Royal Society, and a literary scholar by the British Academy. UKRI's panels are designed for breadth but panels assessing very specialist work in a single traditional discipline may have less domain expertise than the specialist academy for that field.

UKRI is typically the best choice when your work has produced genuinely cross-disciplinary outputs that draw on more than one research council's scope, or when your primary output is innovation rather than traditional research publication. A computational social scientist whose models inform economic policy, a health technologist whose device has received NICE approval, or a materials researcher who has co-founded a deep-tech company and holds both publications and patents — these profiles all sit naturally in UKRI's remit because they span the boundaries of the specialist academies.

Assess your tier for the standard route

For the standard UKRI route, Exceptional Talent indicators include: a strong competitive grant record as PI across UKRI or equivalent international funders; a sustained publication, patent, or research output record in a high-impact field; evidence of translational impact — spinout companies, licenses, NHS adoption of research outputs, policy citations; or wide professional recognition (learned society fellowship, major prizes, advisory roles at government or international bodies).

Exceptional Promise indicators include: a competitive early-career fellowship as PI (UKRI Future Leaders Fellowship, MRC Career Development Award, Wellcome Early Career Award); a growing output record with demonstrable trajectory; and strong endorsement from senior researchers or innovators who can speak to your potential. UKRI Promise applicants in innovation and commercialisation contexts often have profiles that differ significantly from traditional academic applicants — a deep-tech founder with two patents and an Innovate UK grant may be a stronger Promise candidate than a postdoc with a longer but narrower publication list.

One of the important nuances of the UKRI standard route is that it recognises that translational impact takes time to accumulate after research is completed. A researcher whose 2020 paper has led to a licensed technology in 2025 that is now being adopted in NHS trusts should document that downstream impact explicitly, even though the research itself was complete years before the application. UKRI panels understand research-to-impact pipelines and will credit impact that is clearly traceable to your research contribution, even if the final adoption happened after your active involvement ended.

Compile your research and innovation evidence pack

UKRI evidence packs vary more than any other endorsing body because of the breadth of the remit. Depending on your profile, include as relevant: publications (journal articles, preprints, reports); patents and IP with commercialisation evidence; competitive grants as PI or named investigator; spinout companies or licensed technologies with evidence of commercial traction; policy citations or government advisory roles; health technology assessment reports or NICE adoption; Innovate UK-funded project deliverables; and professional recognition (fellowships, prizes, keynotes, standards contributions).

For interdisciplinary researchers, explicitly map each piece of evidence to its significance — the panel may not be specialists in every discipline your work touches. A sentence explaining that 'Journal X is the leading publication in Y field, with impact factor Z' takes thirty seconds to write and removes ambiguity for a panel member who is an expert in a related but distinct area.

For innovation-track applicants, commercial traction evidence is particularly important. Include: Innovate UK grant awards with project titles and amounts; patents with current licensing or commercialisation status; investor letters or cap table documentation for spinouts (appropriately redacted); customer or adoption evidence such as NHS procurement references, contracts with named clients, or user numbers for deployed products; and any regulatory approvals (MHRA, CE, FDA) for medical devices or technologies. The UKRI panel for innovation tracks includes members from industry and technology transfer, not just academia — they will understand commercial evidence and weigh it appropriately.

Select three senior referees with relevant expertise

Three referees, at least two external to your current employer. For UKRI applications, referee breadth can be valuable: a letter from a leading academic in your primary discipline, one from a senior figure in an industry or policy organisation where your work has had impact, and one from an international researcher in your field provides coverage across the different dimensions of UKRI's assessment.

Brief each referee carefully on your chosen tier and the specific evidence you want them to address. For innovation-track applicants, a letter from a chief technology officer, chief medical officer, or senior investor who can speak to the real-world impact of your research is often more valuable than a third academic letter.

The multi-domain nature of UKRI applications means referee selection requires more thought than for specialist academy routes. Three academic letters that all speak to the same narrow publication record may not adequately cover the breadth of your UKRI application, particularly if part of its strength is in translational impact or commercial innovation. Think about which three people can collectively cover all the key dimensions of your profile — academic quality, real-world impact, and international standing — rather than which three people know you best.

Write your research and innovation statement

The standard route research statement (800–1,000 words) should: explain your research or innovation programme and why it matters; make the explicit case for your tier, citing the specific evidence that establishes you as a recognised or emerging leader; and describe your UK contribution plan — what research, innovation, or translational work you plan to pursue in the UK, and how UKRI funding, UK academic or industry partnerships, or NHS/government engagement are central to it.

For innovation-track applicants, the UK contribution plan section is especially important. UKRI endorses in the national innovation interest — a plan to commercialise a technology through a UK spinout, apply for Innovate UK funding, or work with NHS trusts to translate a diagnostic tool demonstrates exactly the kind of contribution UKRI is accountable for endorsing.

For interdisciplinary researchers, the statement should weave together the different threads of your work into a coherent narrative — not present separate academic and commercial identities in parallel. The most effective UKRI statements show how the research, the innovation, and the policy or clinical impact form a single coherent programme of work with a clear logic connecting them. If your research drives commercial outcomes which in turn fund further research, describe that cycle explicitly. UKRI's mandate is to support exactly this kind of research-innovation ecosystem.

Submit via the UKVI portal selecting UKRI

Submit through the UK Visas and Immigration online portal, selecting UKRI as your endorsing body. Upload your CV (maximum 3 pages), research statement, evidence pack, and grant list. For the EFR route, upload documentation of your qualifying award. UKRI contacts your referees directly.

For EFR applicants, attach the grant letter or contract confirming the award, the project title, and the dates. UKRI may ask for a brief confirmation from your institution that the award is current if applying while the grant is still active.

Standard route applicants should ensure their evidence pack is clearly organised by category — publications, grants, patents, commercial evidence, recognition — rather than presented in a single chronological CV style. UKRI panels process interdisciplinary applications by assessing different evidence types with different expertise; a well-organised pack reduces the cognitive load on reviewers and ensures no category of evidence is overlooked.

Await UKRI decision and apply to the Home Office

EFR applications typically receive decisions in 3–4 weeks. Standard route applications take approximately 8 weeks. All UKRI endorsees — EFR and standard, Talent and Promise — qualify for the 3-year ILR fast track. The research absence exception to the 180-day rule also applies: time spent abroad for work-related research activities does not count towards the absence limit, which is particularly relevant for researchers who divide time between international collaborators or fieldwork locations.

After receiving your visa, maintain records of your research-related travel abroad separately from personal travel. When you apply for ILR, you will need to demonstrate that absences exceeding 180 days in any 12-month period were work-related. UKRI endorsees who divide time between UK institutions and international research partners — at CERN, overseas universities, WHO, or international clinical sites — benefit substantially from this exemption, but only if it is properly documented at the time of travel rather than reconstructed from memory years later.